Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer

Simple item page
dc.contributor.authorBhardwaj, Megha
dc.contributor.authorGies, Anton
dc.contributor.authorWeigl, Korbinian
dc.contributor.authorTikk, Kaja
dc.contributor.authorBenner, Axel
dc.contributor.authorSchrotz-King, Petra
dc.contributor.authorBorchers, Christoph H.
dc.contributor.authorBrenner, Hermann
dc.date.accessioned2021-12-09T23:08:10Z
dc.date.available2021-12-09T23:08:10Z
dc.date.copyright2019en_US
dc.date.issued2019
dc.descriptionThe authors acknowledge the cooperation of gastroenterology practices and clinics in patient recruitment and of Labor Limbach in sample collection. They also thank Katja Butterbach, Katarina Cuk, Ulrike Schlesselmann, Sabine Eichenherr, Romana Kimmel and Rosa Orihuela Vicente for their excellent work in laboratory preparation of blood samples and Isabel Lerch, Susanne Köhler, Utz Benscheid, Jason Hochhaus, and Maria Kuschel for their contribution in data collection, monitoring, and documentation. C.H.B. and the University of Victoria-Genome British Columbia Proteomics Centre are grateful to Genome Canada and Genome British Columbia for financial support through the Genomics Innovation Network (project codes 204PRO for operations and 214PRO for technology development) and the Genomics Technology Platform (264PRO). C.H.B. is also grateful for support from the Leading Edge Endowment Fund, and the Segal McGill Chair in Molecular Oncology at McGill University (Montreal, QC, Canada). C.H.B. is also grateful for support from the Warren Y. Soper Charitable Trust and the Alvin Segal Family Foundation to the Jewish General Hospital (Montreal, QC, Canada).en_US
dc.description.abstractObjective: Plasma protein biomarkers could be an efficient alternative for population-based screening for early detection of colorectal cancer (CRC). The objective of this study was to evaluate and validate plasma proteins individually and as a signature for early detection of CRC. Methods: In a three-stage design, proteins were measured firstly by liquid chromatography/multiple reaction monitoring-mass spectrometry (LC/MRM-MS) and later by proximity extension assay (PEA) in a discovery set consisting of 96 newly diagnosed CRC cases and 94 controls free of neoplasms at screening colonoscopy. Two algorithms (one for each measurement method) were derived by Lasso regression and .632+ bootstrap based on 11 proteins that were included in both the LC/MRM-MS and PEA measurements. Additionally, another algorithm was constructed from the same eleven biomarkers plus amphireglin, the most promising protein marker in the PEA measurements that had not been available from the LC/MRM-MS measurements. Lastly the three prediction signatures were validated with PEA in independent samples of participants of screening colonoscopy (CRC (n = 56), advanced adenoma (n = 101), and participants free of neoplasm (n = 102)). Results: The same four proteins were included in all three prediction signatures; mannan binding lectin serine protease 1, osteopontin, serum paraoxonase lactonase 3 and transferrin receptor protein 1, and the third prediction signature additionally included amphiregulin. In the independent validation set from a true screening setting, the five-marker blood-based signature including AREG presented areas under the curves of 0.82 (95% CI, 0.74–0.89), 0.86 (95% CI, 0.77–0.92) and 0.76 (95% CI, 0.64–0.86) for all, early and late stages CRC, respectively. Conclusion: Two different measurement methods consistently identified four protein markers and an algorithm additionally including amphiregulin, a marker measured by PEA only, showed promising performance for detecting early stage CRC in an independent validation in a true screening setting. These proteins may be potential candidates for blood-based tests for early detection of CRC.en_US
dc.description.reviewstatusRevieweden_US
dc.description.scholarlevelFacultyen_US
dc.description.sponsorshipThe BLITZ study was partly funded by grants from the German Research Council (DFG, grant No. BR1704/16-1). The ASTER and iDa studies were funded by the German Federal Ministry of Education and Research through the German Cancer Consortium (DKTK).en_US
dc.identifier.citationBhardwaj, M., Gies, A., Weigl, K., Tikk, K., Benner, A., Schrotz-King, P., Borchers, C. H., & Brenner, H. (2019). Evaluation and validation of plasma proteins using two different protein detection methods for early detection of colorectal cancer. Cancers, 11(10). https://doi.org/10.3390/cancers11101426en_US
dc.identifier.urihttps://doi.org/10.3390/cancers11101426
dc.identifier.urihttp://hdl.handle.net/1828/13581
dc.language.isoenen_US
dc.publisherCancersen_US
dc.subjectcolorectal cancer
dc.subjectearly detection
dc.subjectscreening
dc.subjectbiomarkers
dc.subjectprevention
dc.subjectproximity extension assay
dc.subjectLC/MRM-MS
dc.subjectproteomics
dc.subjectUVic Genome BC Proteomics Centre
dc.subject.departmentDepartment of Biochemistry and Microbiology
dc.titleEvaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Canceren_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Bhardwaj_Megha_Cancers_2019.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Faculty and Staff Publications
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.